132 related articles for article (PubMed ID: 16190507)
1. Predicting the risk of prostate cancer on biopsy.
Ebell MH
Am Fam Physician; 2005 Sep; 72(6):1091-2. PubMed ID: 16190507
[No Abstract] [Full Text] [Related]
2. Making sense of prostate specific antigen: improving its predictive value in patients undergoing prostate biopsy.
Nam RK; Toi A; Trachtenberg J; Klotz LH; Jewett MA; Emami M; Sugar L; Sweet J; Pond GR; Narod SA
J Urol; 2006 Feb; 175(2):489-94. PubMed ID: 16406978
[TBL] [Abstract][Full Text] [Related]
3. Re: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
Singh A
Can J Urol; 2009 Jun; 16(3):4659. PubMed ID: 19497173
[No Abstract] [Full Text] [Related]
4. Role of free prostate-specific antigen measurement in prostate-specific antigen screening for prostate cancer.
Johnson L
Clin Prostate Cancer; 2002 Dec; 1(3):142-4. PubMed ID: 15046688
[No Abstract] [Full Text] [Related]
5. Preliminary results of a novel method to estimate the probability of prostate cancer in men with elevated serum PSA values.
Spyropoulos E; Dellis AE
Eur Urol; 2008 Sep; 54(3):701-2. PubMed ID: 18403093
[No Abstract] [Full Text] [Related]
6. What is the value of screening for prostate cancer in the US?
Albertsen PC
Nat Clin Pract Oncol; 2005 Nov; 2(11):536-7. PubMed ID: 16270077
[No Abstract] [Full Text] [Related]
7. Editorial comment on: preliminary results of a novel method to estimate the probability of prostate cancer in men with elevated serum PSA values.
Chun FK; Briganti A
Eur Urol; 2008 Sep; 54(3):702. PubMed ID: 18403097
[No Abstract] [Full Text] [Related]
8. Defining increased future risk for prostate cancer: evidence from a population based screening cohort.
Schröder FH; Roobol MJ; Andriole GL; Fleshner N
J Urol; 2009 Jan; 181(1):69-74; discussion 74. PubMed ID: 19012915
[TBL] [Abstract][Full Text] [Related]
9. It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer.
Thompson IM; Ankerst DP; Etzioni R; Wang T
J Urol; 2008 Oct; 180(4):1219-22. PubMed ID: 18707707
[No Abstract] [Full Text] [Related]
10. The use of nomograms in the detection of prostate cancer.
Roobol MJ
Prostate; 2006 Sep; 66(12):1266-7. PubMed ID: 16752374
[No Abstract] [Full Text] [Related]
11. Prostate specific antigen velocity threshold for predicting prostate cancer in young men.
Loeb S; Roehl KA; Catalona WJ; Nadler RB
J Urol; 2007 Mar; 177(3):899-902. PubMed ID: 17296371
[TBL] [Abstract][Full Text] [Related]
12. Can we accurately identify men with low risk prostate cancer?
Neal DE
J Urol; 2008 Oct; 180(4):1217-8. PubMed ID: 18707718
[No Abstract] [Full Text] [Related]
13. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.
D'Amico AV; Chen MH
J Clin Oncol; 2009 Aug; 27(22):3575-6. PubMed ID: 19506151
[No Abstract] [Full Text] [Related]
15. Assessing risk: does this patient have prostate cancer?
Carter HB
J Natl Cancer Inst; 2006 Apr; 98(8):506-7. PubMed ID: 16622114
[No Abstract] [Full Text] [Related]
16. Editorial comment on: prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
Rittmaster R
Eur Urol; 2008 Sep; 54(3):514-5. PubMed ID: 18585846
[No Abstract] [Full Text] [Related]
17. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC).
Roobol MJ; Zappa M; Määttänen L; Ciatto S
Prostate; 2007 Mar; 67(4):439-46. PubMed ID: 17192912
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter.
Finne P; Auvinen A; Määttänen L; Tammela TL; Ruutu M; Juusela H; Martikainen P; Hakama M; Stenman UH
Eur Urol; 2008 Aug; 54(2):362-70. PubMed ID: 18006214
[TBL] [Abstract][Full Text] [Related]
19. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
Moul JW; Sun L; Hotaling JM; Fitzsimons NJ; Polascik TJ; Robertson CN; Dahm P; Anscher MS; Mouraviev V; Pappas PA; Albala DM
J Urol; 2007 Feb; 177(2):499-503; discussion 503-4. PubMed ID: 17222618
[TBL] [Abstract][Full Text] [Related]
20. Predicting probability of prostate cancer.
Callas PW; Stanley DE
Urology; 1997 Oct; 50(4):655-6. PubMed ID: 9338753
[No Abstract] [Full Text] [Related]
[Next] [New Search]
